Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada

Johansen, P; Hakan-Bloch, J; Liu, AR; Bech, PG; Persson, S; Leiter, LA

Johansen, P (reprint author), Novo Nordisk AS, Vandtarnsvej 108, DK-2860 Soborg, Denmark.

PHARMACOECONOMICS-OPEN, 2019; 3 (4): 537